Advanced Surgery Technique Dramatically Reduces Cancer Recurrence in Rare Adrenal Tumors
Combining regional surgery with heated chemotherapy cut cancer recurrence from 82% to 0% in adrenal cancer patients.
Summary
Researchers found that combining extensive surgical removal of adrenal cancer with heated chemotherapy delivered directly into the abdomen dramatically reduced cancer recurrence. In a study of 58 patients with adrenocortical carcinoma, those receiving this combined approach had zero local cancer recurrence compared to 82% recurrence in patients receiving standard surgery alone. The technique, called regional adrenalectomy with HIPEC, involves removing the tumor along with surrounding tissues, then washing the abdominal cavity with heated chemotherapy drugs. While the procedure increased surgery time and hospital stay, it significantly improved long-term survival outcomes for this aggressive cancer.
Detailed Summary
Adrenocortical carcinoma is a rare but aggressive cancer affecting the adrenal glands that frequently returns after surgery, making it particularly challenging to treat effectively. This recurrence significantly impacts patient survival and quality of life.
Researchers analyzed 58 patients with stage II and III adrenocortical carcinoma who underwent different surgical approaches. They compared three groups: 11 patients receiving regional adrenalectomy plus heated intraperitoneal chemotherapy (REGHIPEC), 18 receiving regional surgery alone, and 29 receiving standard simple surgery.
The REGHIPEC procedure involves removing the tumor along with surrounding tissues, then delivering heated chemotherapy directly into the abdominal cavity. While this added 80 minutes to surgery time and extended hospital stays by three days, the results were striking. Local cancer recurrence occurred in 0% of REGHIPEC patients, 35% of regional surgery patients, and 82% of simple surgery patients.
Overall cancer recurrence rates were similarly impressive: 18% for REGHIPEC, 50% for regional surgery alone, and 86% for simple surgery. Disease-specific mortality followed the same pattern, with REGHIPEC showing the lowest death rates at 18% compared to 72% for simple surgery.
These findings suggest that aggressive surgical approaches combined with targeted chemotherapy delivery could significantly improve outcomes for patients with this rare cancer. However, the increased surgical complexity and higher complication rates require careful patient selection and experienced surgical teams.
Key Findings
- Combined regional surgery and heated chemotherapy eliminated local cancer recurrence completely
- Overall cancer recurrence dropped from 86% to 18% with the advanced surgical approach
- Disease-specific mortality decreased from 72% to 18% with comprehensive treatment
- Treatment required 80 additional minutes of surgery and 3 extra days hospitalization
Methodology
Retrospective analysis of 58 patients with stage II-III adrenocortical carcinoma comparing three surgical approaches over a median 56-month follow-up period. Patients were grouped by treatment received: regional surgery plus HIPEC, regional surgery alone, or simple adrenalectomy.
Study Limitations
Small sample size and retrospective design limit generalizability. The REGHIPEC group had higher major complications (27% vs 6%), requiring careful patient selection. Results need validation in larger prospective studies before widespread adoption.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.